Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

73 questions · 73 findings · 9 reviews

No studies found 17 · 23.3%GRADE not reported 9 · 12.3%Very low 17 · 23.3%Low 23 · 31.5%Moderate 7 · 9.6%High 0 · 0%

Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate

Number of participants with any adverse event (primary tolerability outcome) · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…

Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: adverse events ‐ at least 1 adverse event compared with topical betamethasone dipropionate (moderate certainty).

1 finding from 1 review

Cyclosporin A in orabase (topical) vs Placebo (orabase)

Oral ulcers (number, size, healing time) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • Ergun 1997 (cyclosporin A in orabase vs placebo orabase, 24 patients; high risk of reporting bias): no data were presented; authors reported no clinical improvement in the number, size, and healing time of ulcers for…
    1 study · 24 participants
    GRADE not reported

Cyclosporin (systemic; 10 mg/kg/day for 16 weeks) vs Colchicine (systemic; 1 mg daily)

Alleviation of oral aphthous ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

Cyclosporin (systemic; 10 mg/kg/day for 16 weeks) led to higher alleviation of oral aphthous ulcers compared with colchicine (systemic; 1 mg daily); GRADE not reported.

1 finding from 1 review

Topical interventions (sucralfate, interferon-alpha, cyclosporin A) vs placebo

Episode frequency associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
    Studies not reported
    GRADE not reported

Topical interventions (sucralfate, interferon-alpha, cyclosporin A) vs placebo

Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
    Studies not reported
    GRADE not reported

Topical interventions (sucralfate, interferon-alpha, cyclosporin A) vs placebo

Pain associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
    Studies not reported
    GRADE not reported

Topical interventions (sucralfate, interferon-alpha, cyclosporin A) vs placebo

Episode duration associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
    Studies not reported
    GRADE not reported

Summary of findings table ‐ Oral classical immunosuppressants (prednisolone or cyclosporine) vs placebo

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

It is very uncertain whether summary of findings table ‐ Oral classical immunosuppressants… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).

1 finding from 1 review

Higher JIA disease activity/severity (e.g., high JADAS/activity scores, polyarticular RF-negative subtype, active disease, anti-TNFalpha or cyclosporine medication) vs Lower JIA disease activity / inactive or milder JIA

Prevalence and severity of oral and TMJ diseases/conditions (periodontal status and dental caries) · Children and adolescents with juvenile idiopathic arthritis (JIA)

Some studies suggested greater JIA disease activity/severity (and certain medications) was associated with worse periodontal and caries outcomes, but small samples meant no solid conclusion could be drawn (ungraded).

1 finding from 1 review